High on Treatment Platelet Reactivity Following Peripheral Endovascular Procedures
NCT ID: NCT01744613
Last Updated: 2013-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2010-01-31
2013-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)
NCT01463150
Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI).
NCT01109784
Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment
NCT01304472
Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention
NCT01505790
Evaluating Additional Platelet Inhibition in Patients With High Platelet Reactivity Undergoing Percutaneous Coronary Intervention
NCT01339026
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Will include patients with PRU values above the optimal cut-off value determined by ROC analysis
No interventions assigned to this group
Group B
Will include patients with PRU values below the optimal cut-off value determined by ROC analysis.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients receiving Clopidogrel per os 75 mg daily at least 1 month prior and 1 year after the procedure.
Exclusion Criteria
* Coagulation disorders
* Known allergy to clopidogrel
* Failure to comply with the antiplatelet treatment protocol
* Aortoiliac disease
18 Years
84 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Patras
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
SIABLIS DIMITRIOS
Dimitrios Siablis, Professor of Radiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dimitrios Siablis, MD, PhD
Role: STUDY_DIRECTOR
University Hospital of Patras
Dimitrios Karnabatidis, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital of Patras
Stavros Spiliopoulos, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital of Patras
Georgios Pastromas, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital of Patras
Konstantinos Katsanos, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital of Patras
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Patras University Hospital
Rio, Achaia, Greece
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Spiliopoulos S, Pastromas G, Katsanos K, Kitrou P, Karnabatidis D, Siablis D. Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity. J Am Coll Cardiol. 2013 Jun 18;61(24):2428-2434. doi: 10.1016/j.jacc.2013.03.036. Epub 2013 Apr 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
822
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.